Journal article
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
The New England journal of medicine, Vol.349(25), pp.2387-2398
12/18/2003
DOI: 10.1056/NEJMoa030656
PMID: 14681504
Abstract
BACKGROUND: Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5α-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown. METHODS: We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia. RESULTS: The risk of overall clinical progression - defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection - was significantly reduced by doxazosin (39 percent risk reduction, P≤0.001) and finasteride (34 percent risk reduction, P=0.002), as compared with placebo. The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the need for invasive therapy were significantly reduced by combination therapy (P<0.001) and finasteride (P<0.001) but not by doxazosin. Doxazosin (P<0.001), finasteride (P=0.001), and combination therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P[removed]
Details
- Title: Subtitle
- The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
- Creators
- John D Mcconnell - The University of Texas Southwestern Medical CenterClaus G Roehrborn - The University of Texas Southwestern Medical CenterE. David Crawford - University of Colorado DenverAnanias Diokno - William Beaumont HospitalJohn P Foley - Brooke Army Medical CenterHarris E Foster - Yale UniversityStephen C Jacobs - University of Maryland, BaltimoreSteven A Kaplan - New York Hospital QueensKarl J Kreder - University of IowaMichael M Lieber - Mayo Clinic in ArizonaM. Scott Lucia - University of Colorado DenverGary J Miller - University of Colorado HealthOliver M Bautista - George Washington UniversityMani Menon - Henry Ford Health SystemDouglas F Milam - Vanderbilt UniversityJoe W Ramsdell - University of California San DiegoNoah S Schenkman - Walter Reed Army Institute of ResearchKevin M Slawin - Baylor College of MedicineJoseph A Smith - Vanderbilt UniversityGerald L Andriole - Washington University in St. LouisChristopher M Dixon - New York University, New York, United StatesJohn W Kusek - National Institutes of HealthHerbert Lepor - New York UniversityKevin T Mcvary - Northwestern UniversityLeroy M Nyberg - National Institutes of HealthHarry S Clarke - Emory UniversityMedical Therapy of Prostatic Symptoms (MTOPS) Research Group
- Resource Type
- Journal article
- Publication Details
- The New England journal of medicine, Vol.349(25), pp.2387-2398
- DOI
- 10.1056/NEJMoa030656
- PMID
- 14681504
- NLM abbreviation
- N Engl J Med
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Publisher
- Massachusetts Medical Society
- Language
- English
- Date published
- 12/18/2003
- Academic Unit
- Obstetrics and Gynecology; Urology
- Record Identifier
- 9984383902702771
Metrics
14 Record Views